"Baylor Scott & White Charles A. Sammons Cancer Center – Dallas is a leading cancer center in North Texas. Our unmatched cancer programs across outpatient and inpatient care make us one of the best cancer treatment centers in Texas, offering quality, coordinated cancer care across the patient journey. Every cancer patient has a unique set of circumstances that require a personalized plan of care. The multidisciplinary team of top cancer physicians on the centers’ medical staffs and the oncology-trained staff across our Cancer Research & Treatment Centers and other specialized programs take your cancer treatment approach to the next level. Learn more about how we can help you and your family, wherever you are in your cancer journey."

During the past decade, Baylor Sammons Cancer Center conducted 45 clinical trials. In the 10-year time frame, 45 clinical trials started and 35 clinical trials were completed, i.e. on average, 77.8% percent of trials that started reached the finish line to date. In the past 5 years, 9 clinical trials started and 20 clinical trials were completed. i.e. 222.2% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Baylor Sammons Cancer Center" #1 sponsor was "Seagen Inc." with 10 trials, followed by "Baylor Research Institute" with 7 trials sponsored, "Bristol-Myers Squibb" with 5 trials sponsored, "Celgene" with 5 trials sponsored and "Novartis Pharmaceuticals" with 5 trials sponsored. Other sponsors include 49 different institutions and companies that sponsored additional 47 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Baylor Sammons Cancer Center" #1 collaborator was "National Cancer Institute (NCI)" with 4 trials as a collaborator, "Bristol-Myers Squibb" with 3 trials as a collaborator, "Millennium Pharmaceuticals, Inc." with 3 trials as a collaborator, "Merck Sharp & Dohme LLC" with 2 trials as a collaborator and "AbbVie" with 1 trials as a collaborator. Other collaborators include 12 different institutions and companies that were collaborators in the rest 22 trials.

According to Clinical.Site data, the most researched conditions in "Baylor Sammons Cancer Center" are "Multiple Myeloma" (7 trials), "Breast Cancer" (6 trials), "Pancreatic Cancer" (6 trials), "Acute Myelogenous Leukemia" (5 trials) and "Acute Myeloid Leukemia" (4 trials). Many other conditions were trialed in "Baylor Sammons Cancer Center" in a lesser frequency.

Most popular intervention types in "Baylor Sammons Cancer Center" are "Drug" (79 trials), "Biological" (15 trials), "Other" (4 trials), "Procedure" (3 trials) and "Device" (1 trials). Other intervention types were less common.

The name of intervention was led by "Dexamethasone" (6 trials), "brentuximab vedotin" (6 trials), "Lenalidomide" (5 trials), "Rituximab" (5 trials) and "Gemcitabine" (4 trials). Other intervention names were less common.

The vast majority of trials in "Baylor Sammons Cancer Center" are 74 trials for "All" genders, 8 trials for "Female" genders and 3 trials for "Male" genders.

Currently, there are NaN active trials in "Baylor Sammons Cancer Center". 2 are not yet recruiting, 4 are recruiting, 14 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 48 completed trials in Baylor Sammons Cancer Center, 1 suspended trials, and 13 terminated clinical trials to date.

Out of the total trials that were conducted in Baylor Sammons Cancer Center, 28 "Phase 1" clinical trials were conducted, 41 "Phase 2" clinical trials and 24 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 1 trials, and there were also 2 trials that are defined as “Not Applicable".